Evidence map›Paper›PMID 30139742›Full record

ArticleThe Journal of biological chemistry2018

Structure-function analyses reveal a triple β-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design.

Amanda M Roehrkasse, Jason M Booe, Sang-Min Lee, Margaret L Warner, Augen A Pioszak

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists.International journal of molecular sciences · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Structure and Dynamics of Adrenomedullin Receptors AMACS pharmacology & translational science · 2020
    Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amanda M RoehrkasseFrom the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Jason M BooeFrom the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Sang-Min LeeFrom the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Margaret L WarnerFrom the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Augen A PioszakFrom the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 augen-pioszak@ouhsc.edu.
University of Oklahoma Health Sciences Center · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Structure-Function Studies of MsvR, a Methanogen-Specific Transcriptional RegulaP20GM103640 · NIGMS · UNIVERSITY OF OKLAHOMA · PI THOMAS, LEONARD M · 2012 to 2021
$20.4M
RAMP-altered Class B GPCR Hormone RecognitionR01GM104251 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PIOSZAK, AUGEN A · 2012 to 2024
$4.2M
NCI NIH HHS P30 CA225520NIGMS NIH HHS P20 GM103640NIGMS NIH HHS R01 GM104251
6 · The paper itself

Abstract

The cardioprotective vasodilator peptide adrenomedullin 2/intermedin (AM2/IMD) and the related adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) signal through three heterodimeric receptors comprising the calcitonin receptor-like class B G protein-coupled receptor (CLR) and a variable receptor activity-modifying protein (RAMP1, -2, or -3) that determines ligand selectivity. The CGRP receptor (RAMP1:CLR) favors CGRP binding, whereas the AM

Indexed as

AdrenomedullinCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinDrug DesignHEK293 CellsHumansLigandsMutagenesis, Site-DirectedPeptide HormonesProtein BindingProtein ConformationProtein EngineeringReceptor Activity-Modifying Protein 1Receptor Activity-Modifying Protein 2Receptor Activity-Modifying Protein 3Receptor Activity-Modifying ProteinsADM2 protein, humanADM protein, humanAdrenomedullinCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinCALCRL protein, humanLigandsPeptide HormonesRAMP1 protein, humanRAMP2 protein, humanRAMP3 protein, humanReceptor Activity-Modifying Protein 1Receptor Activity-Modifying Protein 2Receptor Activity-Modifying Protein 3Receptor Activity-Modifying ProteinsReceptors, Adrenomedullincardioprotectionclass B GPCRfluorescence anisotropyG protein-coupled receptor (GPCR)molecular pharmacologypeptide hormoneprotein engineeringreceptor activity-modifying proteinreceptor structure-functionsignal transductionvasodilationX-ray crystallography

Identifiers

PMID30139742
PMCPMC6187615
OpenAlexW2888242583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.